Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis

  1. Jasmine C Wong
  2. Kelley M Weinfurtner
  3. Maria del pilar Alzamora
  4. Scott C Kogan
  5. Michael R Burgess
  6. Yan Zhang
  7. Joy Nakitandwe
  8. Jing Ma
  9. Jinjun Cheng
  10. Shann-Ching Chen
  11. Theodore T Ho
  12. Johanna Flach
  13. Damien Reynaud
  14. Emmanuelle Passegué
  15. James R Downing
  16. Kevin Shannon  Is a corresponding author
  1. University of California, San Francisco, United States
  2. Celgene Corporation, United States
  3. Chinese Academy of Sciences, China
  4. St. Jude Children's Research Hospital, United States
  5. Thermo Fisher Scientific, United States
  6. Institute of Experimental Cancer Research, Germany
  7. Cincinnati Children's Hospital Medical Center, United States

Abstract

Chromosome 7 deletions are highly prevalent in myelodysplastic syndrome (MDS), and likely contribute to aberrant growth through haploinsufficiency. We generated mice with a heterozygous germline deletion of a 2 Mb interval of chromosome band 5A3 syntenic to a commonly deleted segment of human 7q22, and show that mutant hematopoietic cells exhibit cardinal features of MDS. Specifically, the long-term hematopoietic stem cell (HSC) compartment is expanded in 5A3+/del mice, and the distribution of myeloid progenitors (MP) is altered. 5A3+/del HSCs are defective for lymphoid repopulating potential and show a myeloid lineage output bias. These cell autonomous abnormalities are exacerbated by physiologic aging and upon serial transplantation. The 5A3 deletion partially rescues defective repopulation in Gata2 mutant mice. 5A3+/del hematopoietic cells exhibit decreased expression of oxidative phosphorylation genes, increased levels of reactive oxygen species, and perturbed oxygen consumption. These studies provide the first functional data linking 7q22 deletions to MDS pathogenesis.

Article and author information

Author details

  1. Jasmine C Wong

    Department of Pediatrics, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Kelley M Weinfurtner

    Department of Pediatrics, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Maria del pilar Alzamora

    Department of Pediatrics, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Scott C Kogan

    Department of Laboratory Medicine, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Michael R Burgess

    Celgene Corporation, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Yan Zhang

    Unit of Hematopoietic Stem Cell and Transgenic Animal Models, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Joy Nakitandwe

    Department of Pathology, St. Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Jing Ma

    Department of Pathology, St. Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Jinjun Cheng

    Department of Pathology, St. Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Shann-Ching Chen

    Thermo Fisher Scientific, South San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Theodore T Ho

    Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Department of Medicine, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Johanna Flach

    Comprehensive Cancer Center, Institute of Experimental Cancer Research, Ulm, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Damien Reynaud

    Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Emmanuelle Passegué

    Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Department of Medicine, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. James R Downing

    Department of Pathology, St. Jude Children's Research Hospital, Memphis, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Kevin Shannon

    Department of Pediatrics, University of California, San Francisco, San Francisco, United States
    For correspondence
    ShannonK@peds.ucsf.edu
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: Study mice were housed in a specific pathogen-free facility at the University of California San Francisco, and all animal experiments were conducted in strict accordance with the protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of California, San Francisco (Approval number: AN091877-03).

Copyright

© 2015, Wong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,021
    views
  • 384
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jasmine C Wong
  2. Kelley M Weinfurtner
  3. Maria del pilar Alzamora
  4. Scott C Kogan
  5. Michael R Burgess
  6. Yan Zhang
  7. Joy Nakitandwe
  8. Jing Ma
  9. Jinjun Cheng
  10. Shann-Ching Chen
  11. Theodore T Ho
  12. Johanna Flach
  13. Damien Reynaud
  14. Emmanuelle Passegué
  15. James R Downing
  16. Kevin Shannon
(2015)
Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis
eLife 4:e07839.
https://doi.org/10.7554/eLife.07839

Share this article

https://doi.org/10.7554/eLife.07839

Further reading

    1. Cell Biology
    2. Chromosomes and Gene Expression
    Bhumil Patel, Maryke Grobler ... Needhi Bhalla
    Research Article

    Meiotic crossover recombination is essential for both accurate chromosome segregation and the generation of new haplotypes for natural selection to act upon. This requirement is known as crossover assurance and is one example of crossover control. While the conserved role of the ATPase, PCH-2, during meiotic prophase has been enigmatic, a universal phenotype when pch-2 or its orthologs are mutated is a change in the number and distribution of meiotic crossovers. Here, we show that PCH-2 controls the number and distribution of crossovers by antagonizing their formation. This antagonism produces different effects at different stages of meiotic prophase: early in meiotic prophase, PCH-2 prevents double-strand breaks from becoming crossover-eligible intermediates, limiting crossover formation at sites of initial double-strand break formation and homolog interactions. Later in meiotic prophase, PCH-2 winnows the number of crossover-eligible intermediates, contributing to the designation of crossovers and ultimately, crossover assurance. We also demonstrate that PCH-2 accomplishes this regulation through the meiotic HORMAD, HIM-3. Our data strongly support a model in which PCH-2’s conserved role is to remodel meiotic HORMADs throughout meiotic prophase to destabilize crossover-eligible precursors and coordinate meiotic recombination with synapsis, ensuring the progressive implementation of meiotic recombination and explaining its function in the pachytene checkpoint and crossover control.

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ashley L Cook, Surojit Sur ... Nicolas Wyhs
    Research Article

    Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.